Similar Stories to Fda Grants New Indication For Pfizer, Bristol-myers Squibb Drug on Bing News

The FDA today approved an expanded indication for  the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) [...]

Topics:  fda    eliquis bristol-myers squibb   pfizer    apixaban   dvt   pe   indication   venous   
BING NEWS:
  • Bristol Myers Squibb Nabs FDA Accelerated Approval for Breyanzi in Follicular Lymphoma
    The agency approved the autologous CAR T-cell therapy after around 96 percent of patients in the Phase II TRANSCEND-FL trial responded to it.
    05/16/2024 - 6:27 am | View Link
  • FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
    the FDA granted accelerated approval to Bristol Myers Squibb Co’s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed ...
    05/16/2024 - 4:56 am | View Link
  • Hold Rating on Bristol-Myers Squibb Amid Mounting Competition and Flat Growth Projections
    Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target is $67.00. Steve Scala has given his Hold rating due to a ...
    05/15/2024 - 10:35 pm | View Link
  • Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
    Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for B ...
    05/15/2024 - 1:57 pm | View Link
  • Bristol Myers' Breyanzi gains additional indication for follicular lymphoma
    The U.S. FDA has granted accelerated approval to Bristol-Myers Squibb's gene therapy Breyanzi (lisocabtagene maraleucel) for follicular lymphoma in patients who have received at least two prior lines ...
    05/15/2024 - 10:36 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News